The chimeric TF TCF3-HLF, which confers treatment resistance in ALL was recently shown to act as a pioneer factor that aberrantly activates a distal Myc enhancer and mediates interaction with the its promoter and therefore its overexpression (229). Here, MYC is linked to acute lymphoblastic leukemia.